Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class
Authors
Keywords
Angiogenesis, Cancer, Lipocalin, Protein engineering, Protein scaffold
Journal
ANGIOGENESIS
Volume 19, Issue 1, Pages 79-94
Publisher
Springer Nature
Online
2015-12-10
DOI
10.1007/s10456-015-9490-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Menagerie of Human Lipocalins: A Natural Protein Scaffold for Molecular Recognition of Physiological Compounds
- (2015) André Schiefner et al. ACCOUNTS OF CHEMICAL RESEARCH
- Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins
- (2013) A. Richter et al. FEBS LETTERS
- Antibodies to watch in 2014
- (2013) Janice M Reichert mAbs
- A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity
- (2013) Shane A. Olwill et al. MOLECULAR CANCER THERAPEUTICS
- First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
- (2013) Klaus Mross et al. PLoS One
- Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
- (2012) Andreas Stahl et al. ANGIOGENESIS
- Combinatorial Design of an Anticalin Directed against the Extra-Domain B for the Specific Targeting of Oncofetal Fibronectin
- (2012) Michaela Gebauer et al. JOURNAL OF MOLECULAR BIOLOGY
- Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies
- (2011) Stacey D Finley et al. BMC Systems Biology
- Endothelial cell activation in a VEGF-A gradient: Relevance to cell fate decisions
- (2010) Ann Akeson et al. MICROVASCULAR RESEARCH
- Development trends for human monoclonal antibody therapeutics
- (2010) Aaron L. Nelson et al. NATURE REVIEWS DRUG DISCOVERY
- A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity
- (2009) Daniel A. Breustedt et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report
- (2009) Ticiana Leal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- High-Affinity Recognition of Lanthanide(III) Chelate Complexes by a Reprogrammed Human Lipocalin 2
- (2009) Hyun Jin Kim et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
- (2009) D. Schonfeld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
- (2008) T. MEYER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started